Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2025
0mins
Source: Globenewswire
Clinical Trial Results: Candel Therapeutics announced positive results from its phase 3 clinical trial of CAN-2409 for localized prostate cancer, showing a statistically significant improvement in disease-free survival compared to placebo, with a 30% reduction in recurrence risk.
Presentation at ASCO: The findings will be presented at the 2025 ASCO Annual Meeting, highlighting the potential of CAN-2409 as a transformative treatment option for patients with intermediate-to-high-risk localized prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
